Hemab Therapeutics

aid: hemab-therapeutics
name: Hemab Therapeutics
description: 'Hemab Therapeutics is a clinical-stage biopharmaceutical company headquartered in Copenhagen, Denmark with a
  US presence in Cambridge, Massachusetts, developing prophylactic antibody-based therapeutics for serious, underserved bleeding
  and thrombotic disorders. Its modality-agnostic approach uses monoclonal and bispecific antibodies to stabilize coagulation
  proteins, prevent their premature breakdown, and direct them to sites of injury. The clinical pipeline targets Glanzmann
  Thrombasthenia (sutacimig, HMB-001), von Willebrand Disease (HMB-002), Factor VII deficiency and heavy menstrual bleeding.
  Hemab publishes a corporate marketing site, an investor relations site, and audience-specific sections for patients, caregivers
  and healthcare providers. It operates no public developer program: there is no developer portal, API reference, machine-readable
  specification, SDK, or webhook surface on any host it controls.'
deliveryModel:
  model: saas
  open_source: false
  commercial: true
  callable_host: false
  label: Hosted service · you call their endpoint
  confidence: medium
  source:
  - pricing
  generated: '2026-08-28'
  method: derived
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source:
  - security
  generated: '2026-09-02'
  method: derived
image: https://cdn.prod.website-files.com/683e244b9c2c9828c10be2ed/68505c0989a11b7e82490360_Webclip.png
url: https://raw.githubusercontent.com/api-evangelist/hemab-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: profiled
x-tier-reason: enrichment-pass-completed-no-api-surface
specificationVersion: '0.20'
created: '2026-08-22'
modified: '2026-08-22'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Clinical Trials
- Healthcare
- Rare Disease
- Hematology
- Denmark
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/hemab-therapeutics-domain-security.yml
- type: LLMsTxt
  url: llms/hemab-therapeutics-llms.txt
- type: Website
  url: https://www.hemab.com/
- type: PrivacyPolicy
  url: https://www.hemab.com/privacy-policy
- type: TermsOfService
  url: https://www.hemab.com/terms-conditions
- type: Support
  url: https://www.hemab.com/contact-us
- type: Blog
  url: https://www.hemab.com/news-media-hub
- type: About
  url: https://www.hemab.com/about-us
- type: InvestorRelations
  url: https://ir.hemab.com
- type: Careers
  url: https://career.hitalento.com/hemab/
- type: LinkedIn
  url: https://www.linkedin.com/company/hemabaps/
- type: Twitter
  url: https://x.com/hemab_tx
- type: SecondaryMarketListing
  url: https://forgeglobal.com/hemab-therapeutics_stock/
x-enrichment:
  date: '2026-08-22'
  status: minimal
  artifacts_added: 3
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: Hemab Therapeutics is a clinical-stage antibody biopharma whose only web properties are a Webflow marketing site
    and a third-party investor-relations host; www.hemab.com returns 404 for every OpenAPI, GraphQL and /.well-known/ path
    probed, and api./developer./docs.hemab.com do not resolve in DNS, so there is no API surface to profile.
  evidence:
  - url: https://www.hemab.com/openapi.json
    status: 404
  - url: https://www.hemab.com/.well-known/api-catalog
    status: 404
  - url: https://www.hemab.com/.well-known/agent-card.json
    status: 404
  - url: https://www.hemab.com/llms.txt
    status: 404
  - url: https://www.hemab.com/
    status: 200
  checked: '2026-08-22'